ArticleACS chemical biology2021
Genomic-Led Discovery of a Novel Glycopeptide Antibiotic by
Article in ACS chemical biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Functional shifts of the dual-substrate phosphoribosyl isomerase PriA from primary to specialized metabolism in rare Actinomycetota.Microbial genomics · 2026Article
- Isolation and characterization of endophytic actinobacteria associated with Artemisia judaica L. ssp. sahariensis from desert regions in Algeria.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- A rare peptide scaffold in kineomicins, the glycopeptide antibiotics produced by Actinokineospora auranticolor DSM 44650.Communications chemistry · 2025Article
- Article
- Complete Genome Assembly ofGenes · 2024Article
- The Impact of Heterologous Regulatory Genes from Lipodepsipeptide Biosynthetic Gene Clusters on the Production of Teicoplanin and A40926.Antibiotics (Basel, Switzerland) · 2024Article
- Modern Trends in Natural Antibiotic Discovery.Life (Basel, Switzerland) · 2023Review
- Cross-Talking of Pathway-Specific Regulators in Glycopeptide Antibiotics (Teicoplanin and A40926) Production.Antibiotics (Basel, Switzerland) · 2023Article
- Article
- Heterologous Expression Reveals Ancient Properties of Tei3—A VanS Ortholog from the Teicoplanin Producer Actinoplanes teichomyceticusInternational journal of molecular sciences · 2022Article
- Biocatalyzed Synthesis of Glycostructures with Anti-infective Activity.Accounts of chemical research · 2022Review
- Production enhancement of the glycopeptide antibiotic A40926 by an engineered Nonomuraea gerenzanensis strain.Biotechnology letters · 2022Article
- Genetics Behind the Glycosylation Patterns in the Biosynthesis of Dalbaheptides.Frontiers in chemistry · 2022Review
- Genomic Insights into the Distribution and Phylogeny of Glycopeptide Resistance Determinants within theAntibiotics (Basel, Switzerland) · 2021Article
- Enhancing Ristomycin A Production by Overexpression of ParB-Like StrR Family Regulators Controlling the Biosynthesis Genes.Applied and environmental microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 3 countries.
Funding
Abstract
Glycopeptide antibiotics (GPAs) are last defense line drugs against multidrug-resistant Gram-positive pathogens. Natural GPAs teicoplanin and vancomycin, as well as semisynthetic oritavancin, telavancin, and dalbavancin, are currently approved for clinical use. Although these antibiotics remain efficient, emergence of novel GPA-resistant pathogens is a question of time. Therefore, it is important to investigate the natural variety of GPAs coming from so-called "rare" actinobacteria. Herein we describe a novel GPA producer-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.